SynthesisInternational ophthalmology2026
Effectiveness of orthokeratology in controlling myopia in adolescents aged 6-18 years: a systematic review and meta-analysis.
Synthesis in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobal childhood myopia is rising, with longer axial length increasing ocular risks. Orthokeratology corrects vision and may slow axial elongation via peripheral defocus, but the efficacy of newer OK lens designs and long-term persistence of effect remain to be comprehensively evaluated.
methodsAdhering to PROSPERO and PRISMA 2020, PubMed, Embase, Web of Science, Scopus, and Cochrane Library were searched through 18 April 2025. Included studies prospectively compared axial-length changes in children (6-18 years) with OK versus single-vision spectacles, soft contact lenses, or conventional OK. Hartung-Knapp-adjusted random-effects meta-analyses were performed, with subgroup, sensitivity, and leave-one-out analyses addressing heterogeneity.
resultsFifteen trials (1,065 participants) met inclusion criteria. At 12 ± 2 months, OK slowed axial elongation by a pooled mean difference (MD) of - 0.15 mm (95% CI - 0.20 to - 0.10; I2 = 90.8%). Five studies with ≥ 24-month follow-up showed a sustained benefit (MD - 0.19 mm, - 0.32 to - 0.06; I2 = 79%). Four head-to-head trials suggested modified OK designs (e.g., smaller optical zones, higher compression factors) provided an additional - 0.12 mm (- 0.23 to - 0.01) at one year, after excluding one discordant soft-lens study. Funnel plots and Egger's tests indicated no small-study bias. Most studies had low risk of bias; limitations included lack of masking and predominantly East-Asian samples.
conclusionsAxial elongation in myopic children is reduced by approximately 0.15 mm in the first year with OK, and this effect persists for up to three years. Modified lens designs may offer additional benefit. Larger, multi-ethnic trials with long-term follow-up and standardised safety reporting are needed.
Indexed as
Identifiers
41619099What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.